With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Moderna may offer substantial upside, but it's essential to consider the associated risks. Since hitting their peak in late ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

The average short interest in the S&P 500 Health Care Index Sector (XLV) dipped slightly in July to 1.95% from 1.96% in June.

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Shares of the biotech Moderna were up on Wednesday, as the Trump administration’s shifting position on messenger RNA-based ...

Mixed options sentiment in Moderna (MRNA), with shares down 9c near $26.80. Options volume relatively light with 20k contracts traded and calls ...

Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in July, followed ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...